Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice,Annals of Neurology

当前位置： X-MOL 学术 › Ann. Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice
Annals of Neurology ( IF 8.1 ) Pub Date : 2023-12-18 , DOI: 10.1002/ana.26860
Michael Benatar ₁ , Lyle W Ostrow _{2,

3} , Joseph W Lewcock _{3,

4} , Frank Bennett _{3,

5} , Jeremy Shefner _{3,

6} , Robert Bowser _{3,

7} , Paul Larkin ₈ , Lucie Bruijn _{3,

9} , Joanne Wuu ₁

Affiliation

To explore whether the utility of neurofilament light chain (NfL), as a biomarker to aid amyotrophic lateral sclerosis (ALS) therapy development, would be enhanced by obtaining formal qualification from the US Food and Drug Administration for a defined context-of-use.

中文翻译：